Surgery for sporadic vestibular schwannoma. Part III: Facial and auditory nerve function by Kunert, Przemysław et al.
Original research article
Surgery for sporadic vestibular schwannoma.
Part III: Facial and auditory nerve function
Przemysław Kunert, Tomasz Dziedzic *, Anna Podgórska, Tomasz Czernicki,
Arkadiusz Nowak, Andrzej Marchel
Department of Neurosurgery, Medical University of Warsaw, Warszawa, Poland
n e u r o l o g i a i n e u r o c h i r u r g i a p o l s k a 4 9 ( 2 0 1 5 ) 3 7 3 – 3 8 0
a r t i c l e i n f o
Article history:
Received 14 June 2015
Accepted 31 August 2015
Available online 6 September 2015
Keywords:
Vestibular schwannoma
Retrosigmoid approach
Functional outcome
Facial nerve
Hearing preservation
a b s t r a c t
Objective: The aim of this analysis was to assess short-term and long-term outcomes with
respect to the preservation of facial and auditory nerve function following surgery for
sporadic vestibular schwannomas.
Material and methods: The study included 220 consecutive patients operated on with the
retrosigmoid (217) or translabyrinthine (3) approach. The mean extrameatal diameter of the
tumor was 30 mm. In 217 patients, gross total resection was performed and near-total in 3.
Before surgery, the facial nerve (CNVII) weakness was found in 18% of patients and only 20%
had serviceable hearing. Intraoperative neurophysiological CNVII monitoring was routinely
used (the last 211 procedures). Intraoperative monitoring of the cochlear nerve function was
used when the preservation of hearing was attempted (45 procedures).
Results: The rate of CNVII continuity loss during surgery was 11%, however, this decreased to
6% in the second half of the series. Facial nerve function deteriorated, in 88% of the patients
shortly after surgery. However, it improved in 87% in follow-up. Delayed CNVII palsy was
found in 5% of the patients and had a good prognosis in 88%. Final satisfactory CNVII
function (CNVII-SF, HB grades I–III) was achieved in 76% of the patients when excluding the
anastomosis results, and 87% when including them. In recent years, the rate of CNVII-SF has
risen to 94%. Non-serviceable hearing was preserved in 49% of the patients, on whom it was
attempted.
Conclusion: Considering the size of the tumors and extent of the resections, the preservation
of CNVII function is currently very high. A close surveillance of CNVII function evolution
following surgery is mandatory, as 2/3 of the patients discharged with deep paresis will need
different face reanimation procedures. The preservation of useful hearing is still problem-
atic, especially in patients with large tumors.
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1. Introduction
The neurosurgical approach to vestibular schwannoma
treatment has essentially come full circle. In the era of
Cushing, the aim of the treatment was to save lives at the
expense of less radical surgery. Subsequently, neurosurgeons
such as Dandy and Olivecrona strived for oncological cures. In
the last decades of the 20th century, thanks to House and
Samii, the aim of the treatment became total tumor resection
with preservation of facial and auditory nerve function.
Currently, a trend toward less radical VS surgery is seen
again, which can be justiﬁed by the benign and slow growing
nature of the tumor, as well as by the reduction of the risk of
facial and auditory nerve dysfunction [1,2]. In these cohorts,
nerve function preservation is exquisite, but only extended
follow-up of 10–20 years can conﬁrm the rationale of this
approach.
The principles of vestibular schwannoma treatment in the
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Table 1 – Facial and auditory nerves function at pre-
sentation.
Auditory nerve
function (AAO-HNS)
Number of patients %
Class A 9 4.1
Class B 36 16.4
Class C 6 2.7
Class D 169 76.8
Facial nerve
function (HB grade)
Number of patients %
I 180 81.8
II 28 (1a) 12.7
III 7 (3a) (1b) 3.2
IV 2 0.9
V 1 (1a) 0.5
VI 2 (2a) 0.9
a Including patients previously operated on and/or treated with
SRS in other center.
b Patient after hypoglossal–facial anastomosis in other center.
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This means that the main goal of the treatment is to assure a
permanent cure by complete tumor resection, as most patients
are middle-aged and still have a long life expectancy. At the
same time, however, attempts are made to preserve facial and
auditory nerve function. The routine use of intraoperative
neurophysiological monitoring methods has made the pres-
ervation of facial and auditory nerve function feasible even
with radical surgery.
The aim of this analysis was to assess short-term and long-
term outcomes with respect to the preservation of facial and
auditory nerve function following surgery for sporadic
vestibular schwannomas.
2. Materials and methods
The group of patients that was analyzed is characterized in the
paper titled: ‘‘Surgery for sporadic vestibular schwannoma. Part I:
General outcome and risk of tumor recurrence.’’ The anatomical
and functional preservation of CNVII was evaluated in three
time frames: intraoperative, in the short term, and in the long
term. One patient was excluded from the intraoperative
analysis due to prior hypoglossal–facial nerve anastomosis
performed at a different hospital (219 patients included). From
the short-term postoperative analysis, one patient who died
shortly after surgery was also excluded (218 patients included).
From the long-term postoperative analysis, one patient lost to
follow-up was additionally excluded (217 patients included).
Facial nerve weakness before surgery was found in 40
(18.2%) patients, including all seven patients who had received
prior treatment for VS in other centers. Only 45 (20%) patients
had serviceable hearing (AAO-HNS: class A and B, Table 1)
before surgery.
2.1. Perioperative management with respect to the
preservation of facial and auditory nerve function
Electroneurography of CNVII and electrically evoked blink
reﬂexes were carried out in the preoperative period. Directlatencies and amplitudes of responses from the orbicularis
oculi, orbicularis oris, and nasalis muscles were registered.
The latencies of the R1 (unilaterally) and R2 (bilaterally) reﬂex
responses were measured and compared. Immediately prior to
surgery, patients were given 32 mg of dexamethasone intra-
venously. After surgery, dexamethasone was administered in
decreasing doses over a period of seven days. Nimodipine was
routinely administered since August 2009 (the last 50 patients),
at a dose of 60 mg four times a day, starting 3 days before
surgery and continuing up to day 7 post-surgery. In duly
justiﬁed cases, i.e., when severe CNVII paresis (HB grades
IV–VI) was observed, despite continuity preservation, intrave-
nous infusion of nimodipine was administered via a central
catheter at a rate of 10 ml (2 mg) nimodipine solution per hour.
Since 1994, intraoperative neurophysiological CNVII func-
tion monitoring was routinely used (the last 211 procedures).
The following parameters were monitored simultaneously:
1. spontaneous EMG activity of the orbicularis oculi and
orbicularis oris muscles with intermittent CNVII stimulation,
2. motor evoked potentials of the orbicularis oris muscle
evoked by transcranial stimulation of the motor cortex, 3.
orbicularis oculi muscle activity following unilateral supraor-
bital nerve stimulation to evaluate the blink reﬂex (short-
latency R1 response).
Sulfacetamide sodium ophthalmic solution 10% was
administered locally every 2–4 h for conjunctivitis prophylaxis
in all patients during a period of 3–7 days after surgery.
Dexpanthenol gel 5% was administered overnight in patients
with eyelid closure insufﬁciency. In these patients, an
additional prophylaxis was applied: a simple cardboard cover
on the eye in 58 patients (in the early years of the series), a
moisture chamber in 24 patients and/or gold plate implanta-
tion in 51 patients.
Early rehabilitation of the facial muscles was introduced in
the ﬁrst day post-surgery in all cases of CNVII paresis. In
patients with severe CNVII weakness, follow-up EMG at 3, 6
and 9 months post-surgery was planned.
Intraoperative monitoring of the cochlear nerve function,
with the use of ABR and/or transtympanic ECochG (since 2004)
Table 2 – Intraoperative anatomical and functional CNVII
preservation.
No intraoperative
monitoring of
CNVII function
Anatomical continuity
preserved
8 (3.7%)
Anatomical continuity
not preserved
0 (0%)
Operations with
monitoring of
CNVII function
Function preserved 156 (71.2%)
Anatomical integrity
preserved only, with
the lack of response
to ﬁnal EMG stimulation
30 (13.7%)
Anatomical integrity
preserved
25 (11.4%)
Table 3 – The facial nerve functions at early and late
follow-up.
CN VII function
(HB grade)
Number (%) Rate of satisfactory
outcome (HB grades I–III)
Early outcomes
I 18 (8.3%) Satisfactory outcome 39%
II 27 (12.4%)
III 40 (18.3%)
IV 72 (33.0%) Unsatisfactory outcome 61%
V 34 (15.6%)
VI 27 (12.4%)
Late outcomes (without CN VII anastomosis results)
I 74 (34.1%) Satisfactory outcome 76%
II 68 (31.3%)
III 23 (10.6%)
IV 11 (5.1%) Unsatisfactory outcome 24%
V 14 (6.5%)a
VI8 27 (12.4%)a
Late outcomes (including CN VII anastomosis results)
I 74 (34%) Satisfactory outcome 87%
II 74b (34%)
III 41c (19%)
IV 14 (7%) Unsatisfactory outcome 13%
V 7 (3%)
VI 7 (3%)
a In many patients with HB grades V–VI facial nerve anastomosis
was performed, but their results are omitted here.
b Including 6 patients with end-to-end CNVII anastomosis.
c Including 20 patients with different types of CNVII anastomosis.
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possible and worth the effort (45 procedures). Nevertheless,
continuity preservation of the auditory nerve was always
attempted when technically possible, independent of the
tumor size and grade of hearing loss.
Treatment outcome was assessed in the following
categories:
1. CNVII continuity preservation during surgery. The outcome
in this case was binary: the continuity could either be
preserved or not preserved. In 3 cases, the facial nerve was
partially damaged, i.e., some ﬁbers were preserved and
some transected. In these patients, end-to-end anastomo-
ses of the transected ﬁbers were made. All 3 cases were
included in the group with preserved continuity, as less
than half of the nerve ﬁbers were transected.
2. CNVII function in the short term. CNVII function was
evaluated at discharge, according to the House–Brackmann
scale (HB).
3. CNVII function in long-term follow-up, i.e., at least 6 months
after surgery. This analysis aims to evaluate treatment
outcome without additional reconstructive procedures of the
facial nerve, but takes into account the natural regeneration
of CNVII only. For this reason, in this part, CNVII anastomosis
results were omitted and those patients were treated as if
still having CNVII palsy. House–Brackmann grades I–III were
deﬁned as a satisfactory outcome (patients with preserved
facial symmetry at rest and able to close their eyelids),
whereas grades IV–VI as unsatisfactory. House–Brackmann
grades I–II were considered as very good results.
4. Delayed CNVII paresis. Delayed CNVII paresis was deﬁned
as a deterioration in facial nerve function of at least one HB
grade, occurring at least 3 days following surgery [4].
5. Relative CNVII function evaluation. CNVII function in the
short term was compared to the preoperative function.
CNVII function in long-term follow-up was compared to the
short-term result. Here, three outcomes were possible:
deterioration, no change, or improvement.
6. Final CNVII functional results. The long-term CNVII
function including the anastomosis results.
7. Evaluation of hearing after surgery. Following surgery,
hearing was evaluated only in patients on whom preserva-
tion of hearing was attempted. In these cases, intraoper-
ative cochlear nerve function monitoring was planned.
Hearing was assessed according to the AAO-HNS scale.
3. Results
3.1. Continuity preservation of the facial nerve
Among 219 patients, continuity preservation was achieved in
194 (88.6%). The facial nerve was transected in 25 (11.4%) cases
with subsequent end-to-end anastomosis during the same
procedure performed on 13 patients. In the ﬁrst eight patients,
surgery was performed without electrophysiological monitor-
ing of the facial nerve function. Nevertheless, structural
continuity was accomplished in all of them. In the remaining
group of 211 patients, with intraoperative monitoring, CNVIIcontinuity was preserved in 186 patients, of whom 156 were
responsive and 30 unresponsive to the ﬁnal intraoperative
EMG stimulation following tumor resection (Table 2). The risk
of CNVII continuity loss decreased to 6% in the second half of
the analyzed series.
Three patients, in whom the CNVII was partially transected
required end-to-end anastomosis of transected ﬁbers. One of
these nerves remained responsive to the ﬁnal intraoperative
stimulation and two nerves were unresponsive.
3.2. Facial nerve function in the short term
At discharge, only 18 (8.3%) patients did not have any CNVII
dysfunction. In the remaining 200 patients (91.7%), we noted
CNVII paresis of varying degrees (HB grades II–VI). Satisfactory
early outcome was noted in 85 (39%) patients (Table 3). In the
Table 4 – Evolution of CNVII function.
Change of CNVII function between admission and
discharge from hospital
Before surgery Early outcome
HB grade Number Change of
CNVII function
Number (%)
I 179 No change 18 (10%)
Deterioration 161 (90%)
II 28 No change 2 (7%)
Deterioration 26 (93%)
III 6 No change 2 (33%)
Deterioration 4 (67%)
IV 2 No change 1(50%)
Deterioration 1(50%)
V 0 No change 0
Deterioration 0
VI 2 No change 2 (100%)
Deterioration 0
Change of CNVII function between discharge from
hospital and late follow-up
Early outcome Late outcome
HB grade Number Change of
CNVII function
Number (%)
I 18 No change 18 (100%)
II 27 Improvement to I8 24 (86%)
No change 3 (14%)
III 40 Improvement to I8–II8 39 (97%)
No change 1 (3%)
IV 72 Improvement to I8–III8 67 (93%)
No change 5 (7%)
V 33 Improvement to I8–III8 13 (39%)
Improvement to IV8a 6 (18%)
No changeb 14 (42%)
VI 27 No changeb 27 (100%)
a Improvement to HB grade IV is not satisfactory.
b This group also contains the patients after CNVII anastomosis,
but their results are not included here.
n e u r o l o g i a i n e u r o c h i r u r g i a p o l s k a 4 9 ( 2 0 1 5 ) 3 7 3 – 3 8 0376remaining 133 (61%) patients, CNVII paresis of HB grades IV–VI
was observed. Despite the routine use of a prophylactic
cardboard cover on the affected eye, ﬁve patients developed
severe conjunctivitis with corneal ulceration requiring oph-
thalmological management. Over the last ﬁve years, no severe
ophthalmological complications occurred in the analyzed
series. Similarly, no severe ophthalmological complications
were found in patients treated with a moisture chamber and/
or gold plate implantation.
3.3. Delayed facial nerve paresis
Occurred in 8 patients (4 men, 4 women), aged from 34 to 67
years old (mean 53 y.o.). If patients in whom a delayed CNVII
paresis was theoretically possible are taken into account (i.e.,
patients with preserved CNVII continuity, function of HB
grades I–IV over the ﬁrst 3 days post-surgery), then the
incidence of this complication was 5% (8/159). The onset of
delayed CNVII paresis varied from 4 days to over 3 weeks
(mean 10 days) after surgery. In 3 patients, delayed CNVII
paresis was found after discharge. This complication was
treated with steroids. A gold plate was implanted in three
patients and a moisture chamber was used in the remaining
patients. In all but one patient, the paresis was absent or
signiﬁcantly decreased at 6-month follow-up. In the long term,
very good CNVII function (HB grades I–II) was achieved in 7
(88%) patients. In the oldest patient in this subgroup, no
spontaneous regeneration of the CNVII was observed. In this
case, HHFA was performed at 10 months following surgery
with good results (HB grade III).
3.4. Facial nerve function in the long term
Until the last follow-up visit, a very good outcome (HB grades I–
II) was found in 142 (65.4%) patients, whereas a satisfactory
outcome (HB grades I–III) in 165 (76%) patients (Table 3). In 53
(24%) patients, effective CNVII regeneration did not occur or
was not possible due to an intraoperative nerve disruption.
3.5. Evolution of facial nerve function from admission to
discharge
Among patients who did not demonstrate CNVII paresis on
admission, deterioration of the CNVII function was noted in
90% (161/179) in the short term after surgery. Among patients
with HB grades II–V weakness on admission, deterioration was
found in 86% (31/36). Two patients, who presented with CNVII
palsy, did not change until discharge (Table 4). An overall
deterioration rate of CNVII function was noted in 192 patients
(88%) directly after surgery.
3.6. Evolution of CNVII function from discharge to the last
follow-up
Results of CNVII anastomosis are not included here. Eighteen
patients had no CNVII paresis (HB grade I) at discharge, which
remained stable in the long term. Until long-term follow-up,
CNVII function improved in 86.5% (149/172) of the patients with
a paresis of HB grades II–V at discharge. Eighty-three percent
of these patients (143/172) had satisfactory nerve function.Among patients with HB grade IV at discharge, only 5 (7%)
patients did not achieve satisfactory regeneration. However,
among patients with HB grade V at discharge, satisfactory
functional improvement was not seen in 20 patients (61%).
The group of 27 patients with HB grade VI at discharge
includes 24 patients with transected nerves, of whom 23 were
eligible for further reconstructive procedures. In one patient,
effective spontaneous regeneration from the healthy side
appeared which led to an improvement to HB grade IV. In the
remaining 3 patients with HB grade VI, successful nerve
regeneration did not occur in the long term in spite of
preserved CNVII continuity (Table 4).
Among the group of 154 patients with preserved CNVII
function conﬁrmed electrophysiologically during surgery,
72 (47%) were discharged with HB grades IV–VI. Of these
72 patients, 16 (22%) had unsatisfactory long-term outcome.
Among the group of patients with preserved nerve
continuity but negative ﬁnal EMG stimulation, 93% (28/30)
had HB grades IV–VI at discharge. Nevertheless, an improve-
ment to HB grades I–III in the long term was not seen in only
25% (7/28).
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with HB grades II–VI at discharge, 148 (85.1%) improved by at
least one HB grade in the long term.
Of the 107 patients with preserved CNVII continuity but
with HB grades IV–VI at discharge, 80 (74.8%) improved to HB
grades I–III in the long term. In other words, in 1 out of 4
patients with a severe CNVII weakness at discharge, satisfac-
tory CNVII regeneration did not occur despite the fact that its
continuity was preserved. If only patients with a CNVII paresis
of HB grades V–VI in the short term are considered, then a
satisfactory regeneration did not occur in as many as 62.9%
(22/35) of the patients, despite the fact that CNVII continuity
was maintained.
3.7. Final CNVII functional results (including anastomosis
results)
Satisfactory outcome was found in 87% of the patients,
including 68% with very good results (HB grades I–II, Table 3).
Satisfactory CNVII function was achieved through various
CNVII anastomosis techniques in 26 patients: end-to-end
anastomosis in 8, end-to-end after partial nerve injury in 2,
HHFA in 11 and HFA in 5.
Among 98 patients operated on over the last 5 years of the
analyzed period, a satisfactory outcome was achieved in 92
(94%), of whom 72 (73%) had HB grades I–II. In 14 patients of
that group, a satisfactory outcome was attributable to CNVII
anastomosis.
3.8. Treatment failure analysis
A critical appraisal of the treatment outcomes shows that in
the long term, a satisfactory CNVII function was not achieved
in 13%, of whom only 10 out of 28 patients had a surgery-
related CNVII interruption. Eight CNVII anastomosis, including
5 end-to-end procedures and 2 myoplastic surgeries were
unsuccessful.
An extratemporal CNVII anastomosis was offered to the
other 7 patients, but they did not consent. They were 4 men and
3 women, aged from 33 to 61 years (mean 48 years). For
comparison, the group of 12 patients who agreed to have
extratemporal CNVII anastomosis included 12 female and 6
male, aged from 18 to 67 years (mean 44 years). Another ﬁve
patients did not come regularly for follow-up visits despite deep
CNVII weakness, which resulted in persistent nerve paresis.
3.9. Hearing preservation
Among 45 patients with useful hearing before surgery and on
whom hearing preservation surgery was attempted, a certain
range of hearing was preserved in 22 (49%). Nevertheless, in all
of these cases, the hearing was not useful after surgery (AAO-
HNS Class D). In the group of patients with preserved hearing,
predominantly small tumors were found: T2 – ﬁve, T3A – ﬁve,
T3B – six, T4A – three, T4B – three, i.e., only 27% of the tumors
were staged at T4. The mean size was 2.1 cm, and the mean
volume 6 cm3. Nine patients with preserved hearing experi-
enced chronic tinnitus unilaterally on the side that was
operated on. In 4 of these patients, the tinnitus was
troublesome.4. Discussion
4.1. Continuity preservation of the facial nerve
The CNVII continuity was preserved in 88.6% of the operated
patients. In the cohort of Samii, encompassing one thousand
vestibular schwannoma surgeries, the anatomical CNVII
continuity was preserved in 93% [3]. A value of over 98% has
been reported in recent studies [5], which is attributable to
less radical surgery [6].
In the subgroup of the last 110 surgeries in our series, the
incidence of CNVII interruption decreased to 6%. This rate can
be regarded as a satisfactory outcome when the size of the
tumors and the radical strategy of surgical treatment are taken
into account.
4.2. Facial nerve function after surgery and its evolution
At discharge, only 39% of the operated patients had a
satisfactory CNVII function. Deterioration of CNVII function
occurs in 9 out of 10 patients immediately after surgery, but if
the CNVII is anatomically preserved, its function improves in 9
out of 10 patients within 6 months. Shortly after surgery, the
majority of patients experience at least a transient CNVII
paresis [7–9]. Therefore, there is a tendency to present only
long-term results, which are much more satisfactory. Out-
comes regarding CNVII function in the short term after
surgery, despite being rarely reported, are important for
several reasons. Until nerve regeneration takes place, patients
should remain under constant care in order to monitor
the evolution of the CNVII function as well as to prevent
ophthalmological complications. This period is also important
for active facial muscle rehabilitation. When no improvement
is found, more radical management for facial reanimation
should be used in a timely manner [10]. Furthermore, CNVII
function at discharge might have a prognostic value with
respect to long-term improvement.
In the long term, three-quarters of the patients from our
series achieved satisfactory functional outcome when exclud-
ing the anastomosis results. When adding the CNVII anasto-
mosis results, the rate of satisfactory CNVII function increases
to 87%. A satisfactory outcome was achieved in 94% over the
last 5 years of the analyzed period. Preservation of very good
CNVII function (HB grades I–II) is achieved in 90% of the cases
at centers specializing in VS surgery. The risk of persistent
CNVII paralysis can be as low as 1.5% [8]. On the other hand, a
meta-analysis performed by Sughrue et al., encompassing
11,873 patients showed that the preservation of a very good
CNVII function in the long term is achieved in 78% of the
patients operated on via the retrosigmoid approach [11]. Gurgel
et al. published a meta-analysis on VS surgery outcomes for
tumors >2.5 cm in relation to surgical approach sites and the
extent of resection. Following RSA, 65% of patients had HB
grades I–II. That group included patients with total and
subtotal resections [12]. In our series, the rate of very good
results was 59% for tumors >2.5 cm and 68% within the group
of the last 50 operations. Moreover, in that group we
performed, as a rule, gross total tumor resections. In the
above-mentioned meta-analysis, only 47% of the patients
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Samii et al., there is still a long journey to successful
management of this demanding disease [13]. The gradual
improvement in the presented outcomes, over a period of more
than 20 years, was not only a result of the multi-faceted progress
in medicine, but was also related to the increasing experience
of surgeons and multi-disciplinary teams. It should be noted
that despite many changes in surgical techniques and periop-
erative care, the studied population is homogenous in three
respects. Firstly, 90% of the procedures were performed by the
same neurosurgeon (AM). Secondly, a strategy toward complete
and durable cure of the disease was consequently implemented
(NTR only 1.4%; STR – 0%). Currently, this strategy is rather rare,
because the proportion of sub- and near-total resections
reported in recent studies has been increasing [6,14]. This
makes it difﬁcult to relate our results on the risk of CNVII
damage to other studies. Thirdly, over the last two decades, the
mean size of the tumor in our series has not decreased
signiﬁcantly; it is still approximately 3 cm. Therefore, our
results can be applied for CNVII function prognostication
following surgery of large vestibular schwannomas.
‘‘Functional vestibular schwannoma surgery’’ assumes that
functional outcome is a greater priority than completeness of
tumor resection [1,2]. Worth noting is a technique of ‘‘near-
total’’ tumor resection. This must be distinguished from
partial or subtotal tumor resections. Near-total resection
means that less than 2% of the tumor mass remains. In
practice, it comes down to less aggressive separation of the
tumor capsule from the CNVII at the site of closest adhesion,
i.e., in the porus acusticus area or along the thinnest part of the
CNVII [6]. This strategy decreases the risk of CNVII transection
and its dysfunction and is not necessarily associated with less
radical surgery. According to the study of Sasaki et al., the
tumor capsule does not contain neoplastic cells [15]. This is
conﬁrmed by other studies in which tumor recurrence
following near-total resection was very low [2,6]. Very good
CNVII function was preserved in 57% of the patients following
total resection and in 77% following near-total resection. The
tumor recurrence rate was 1%, 2% and 40% for GTR, NTR and
STR, respectively [2]. Based on histopathology researches and
clinical reports, it seems that there is a signiﬁcant difference in
safety between GTR and NTR as well as a difference in
oncological efﬁcacy between NTR and STR. For that reason,
NTR can be used in justiﬁed cases because it does not
compromise the main goal of treatment.
Treatment failure analysis yields a number of conclusions.
Firstly, patients with preserved CNVII continuity, but with
severe paresis at discharge, require regular follow-up visits. A
good doctor–patient relationship is the basis for achieving
better treatment outcomes. Samii underlines that inadequate
follow-up care and lack of experience in the treatment of the
paralyzed face are frequent causes of persistent CNVII paresis
[3]. Secondly, unsuccessful anastomosis in CPA is not a
contraindication to subsequent extratemporal anastomosis.
Thirdly, there is a need for a broader multidisciplinary
collaboration with plastic surgeons in order to offer patients
wider access to reconstructive procedures. Fourthly, the
expectations of patients with respect to the reanimation of
the face vary. It seems that some patients are not self-
motivated enough to undertake long-term rehabilitation orfurther reconstructive procedures. In our series, patients who
agreed to have facial reanimation surgery were predominantly
women in their 4th decade of life, whereas among patients
who did not consent to undergo this procedure, male subjects
comprised 57% and the mean age was 55 years old. This might
mean that middle-aged and older males tend to accept
the CNVII weakness rather than pursue further invasive
treatment.
On the other hand, even small but noticeable facial
asymmetry is usually a major problem for patients with low
self-esteem, women, and young patients [16]. For that reason,
each patient should be offered an individual comprehensive
treatment plan. However, it is important to explain to the
patient what can realistically be achieved with respect to facial
reanimation. Moreover, patients should be encouraged to
actively participate throughout the entire treatment process.
4.3. Hearing preservation
Currently, in the age of functional VS surgery, an attempt of
hearing preservation is mandatory [17,18]. On the one hand,
this can be achieved owing to an increasing proportion of
patients with small tumors and serviceable hearing before
surgery. On the other hand, in the Samii series of 1000 patients
with VS, among patients with some preoperative hearing,
some postoperative hearing was preserved in 40%, including
only 2.4% with tumors >3 cm and good postoperative hearing
[18]. In the next 200 patients, the percentage of serviceable
hearing rose to 27–29% in T4 tumors, but the deﬁnition of
useful hearing was more liberal (to 60 dB in PTA and to 40%
SDS) [5]. Moreover, preservation of hearing was the main goal
in certain cases in which Samii performed subtotal resections
[19]. Fukushima and his team tried to preserve hearing in only
1 out of 4 patients with tumors >2 cm. This was achieved in
54% of the patients but at the expense of less radical resection
in 24%. Here, preservation of hearing was deﬁned in the
following way: score of ≤80 dB in pure tone audiometry and
≥40 dB in verbal audiometry [20]. According to a review
published by Khrais and Sanny in 2006, class A–B hearing
(AAO-HNS) was preserved in 25% with a tumor diameter of
10–19 mm and only in 13% with tumors >20 mm [21]. In a
prospective study from 2009 [22], useful hearing was not
preserved in any of the 13 patients with tumors up to 25 mm.
These reports show that the preservation of hearing is a real
challenge for even the most experienced neurosurgeons. In
our series, a certain range of hearing was preserved in 49% of
the patients in whom such an attempt was made but not even
a single patient maintained useful hearing.
Preservation of useful hearing is more likely (37–77%), when
the middle fossa approach is used [17,23]. In comparison,
useful hearing is preserved in 51% of the patients following
stereotactic radiosurgery (SRS), 3–4 years after radiation [24].
On a more extended follow-up after radiosurgery, hearing
diminishes gradually, possibly due to a decreasing rate of
tumor size control and radiosurgery-induced damage of the
cochlea and the cochlear nerve. Recently, it has been shown
that useful hearing is preserved in only 23% of patients 10
years following SRS [25].
To conclude, neurosurgeons operating large VS are cur-
rently placed in a difﬁcult position. They are confronted with
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hearing preservation outcomes in small tumors. Obviously, in
each case when useful hearing is present before surgery, all
efforts should be made to preserve it during surgery. However,
surgery outcomes in large VS are still frustrating. Therefore,
according to the present state of knowledge, two approaches
are possible. Radical resection at the expense of hearing loss
seems reasonable when the cochlear nerve responses in ABR
are lost. If hearing preservation is the main expectation of the
patient then non-radical resection, completed before the
deterioration of ABR wave V, is justiﬁed [6]. For further hearing
preservation rate improvement, modern forms of intraoper-
ative monitoring like transtympanic electrocochleography or
cochlear nerve compound action potentials are crucial [26,27].
However, an attempt to preserve the structural continuity of
the cochlear nerve, even with no detectable responses is
indicated for several reasons: 1. this nerve constitutes an
additional safety layer for the facial nerve, 2. we are not aware
of future hearing prosthesis capabilities, 3. there is experi-
mental evidence of the possibility of cochlear nerve regenera-
tion following intrathecal immunotherapy [3,13,19,28].
5. Conclusions
The risk of facial nerve continuity loss during surgery was 11%,
however, this decreased to 6% in the second half of the series.
Facial nerve function deteriorated, at least temporarily, in 88%
of the patients shortly after surgery. However, it improved in
87% at 6 months follow-up if CNVII was anatomically
preserved. Delayed CNVII paresis was found in 5% of the
patients and had a good prognosis in 88%. Final satisfactory
CNVII function was achieved in 76% when excluding the
anastomosis results and in 87% when including the anasto-
mosis results. In recent years, the percentage of satisfactory
outcomes has risen to 94%. However, in two thirds of the
patients discharged with severe facial paresis (HB grades V–VI),
satisfactory nerve regeneration did not occur despite the fact
that its continuity was maintained. Therefore, a close
surveillance of CNVII function evolution following surgery is
mandatory as there are many possibilities of facial reanima-
tion in different time frames after surgery. A certain range of
hearing can be preserved in half of the patients in whom such
an attempt is made. However, the preservation of useful
hearing is still problematic especially in patients with large
tumors. Considering the size of the tumors and the extent of
the resections, our current results are comparable to those
obtained at specialized centers worldwide.
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